Amplify ETF Trust Amplify Weight Loss Drug & Treatment ETFAmplify ETF Trust Amplify Weight Loss Drug & Treatment ETFAmplify ETF Trust Amplify Weight Loss Drug & Treatment ETF

Amplify ETF Trust Amplify Weight Loss Drug & Treatment ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪3.92 M‬USD
Fund flows (1Y)
‪4.68 M‬USD
Dividend yield (indicated)
0.37%
Discount/Premium to NAV
−0.3%
Shares outstanding
‪180.00 K‬
Expense ratio
0.59%

About Amplify ETF Trust Amplify Weight Loss Drug & Treatment ETF


Issuer
Amplify Holding Co. LLC
Brand
Amplify
Inception date
May 21, 2024
Structure
Open-Ended Fund
Index tracked
VettaFi Weight Loss Drug Index - Benchmark TR Net
Management style
Passive
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Amplify Investments LLC
Distributor
Foreside Fund Services LLC
THNR focuses on the weight loss industry. The fund tracks an index that invests in companies involved in manufacturing and enabling GLP-1 agonist pharmaceutical businesses. GLP-1 agonists seek to lower blood sugar levels, reduce appetite, and promote fullness, with the ultimate potential for weight loss. Starting with an initial universe of companies from the developed markets, the index selects: 1) drug manufacturers, which are firms with GLP-1 agonist drugs that either have been launched or are currently in Food and Drug Administration (FDA) clinical trials, and 2) enablers, which are companies engaged in the outsourced development and manufacturing, as well as the production and distribution of GLP-1 agonist drugs. Drug manufacturers comprise 70% of the portfolio, while enablers cover the remaining 30%. Holdings within each segment are market cap-weighted, subject to individual security capping. The index reconstitutes and rebalances quarterly.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Pharma, biotech & life sciences
Strategy
Vanilla
Geography
Developed Markets
Weighting scheme
Tiered
Selection criteria
Market cap
What's in the fund
Exposure type
StocksBonds, Cash & Other
Health Technology
Stock breakdown by region
48%31%4%15%
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Broaden your horizons with more funds linked to THNR via country, focus, and more.